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Introduction: characteristics of dendritic cells
It is now well established that dendritic cells (DCs) are
pivotal antigen-presenting cells with the unique capacity
to initiate primary as well as secondary immune
responses. ‘Immature’ dendritic cells (iDCs) can be gen-
erated in vitro from CD34+ hematopoietic stem cells or
from CD14+ monocytes by incubation with granulo-
cyte/monocyte-colony-stimulating factor plus tumor
necrosis factor-α or IL-4 for 7 days. In the course of this
differentiation process, the DC precursors lose the
CD34 and CD14 markers and express a number of novel
phenotypic markers and cell-surface receptors [1–4].
After an additional 2 days of CD40 ligation or incubation
with proinflammatory agents such as bacterial
lipopolysaccharide or cytokines such as tumor necrosis
factor-α, the iDCs become mature DCs (mDCs), with
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Chapter summary
This paper presents a brief review of several lines of evidence suggesting that chemokine receptors on
dendritic cells play an important role in breaking tolerance to self and in inducing autoimmunity. First,
we have shown that an idiotypic self-antigen obtained from malignant murine lymphomas, when
covalently linked to selected chemokines or defensins that interact with receptors on immature
dendritic cells (iDCs), has the capacity to break tolerance to self and induce humoral or cell-mediated
anti-tumor responses. Since unlinked antigens mixed with the same chemokines or defensins or
antigens fused with a mutant ligand deficient in receptor-binding capacity were not immunogenic, we
propose that delivery of an antigen coupled to a ligand for receptors on iDCs promotes the processing
and subsequent presentation of the antigen, resulting in immunoadjuvant effects. In a second study,
we observed that two of five aminoacyl tRNA synthetases (aaRSs) – which act as autoantigens to
which some patients with myositis have autoantibodies – were chemotactic for activated monocytes,
T cells, and iDCs. These aaRSs interacted with either CC chemokine receptor (CCR)5 or CCR3, as
was shown by desensitization with chemokines and the response of cell lines transfected with the
chemokine receptor. Presumably, these autoantigens therefore have the capacity to attract
inflammatory cells, including iDCs, to infiltrate affected muscle cells. These observations suggest the
hypothesis that antigens delivered to receptors on iDCs are potent immunogens capable of breaking
self-tolerance to tumor antigens to induce autoimmune diseases.
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consistent changes in their phenotypic markers as
shown in Fig. 1.
The differences in the functional capabilities of iDCs and
mDCs are relevant to understanding their respective roles in
adaptive immunity and autoimmunity [2]. The iDCs can
phagocytose particulate and larger soluble antigens and
can enzymatically process them to generate small peptide
fragments that can be presented to T cells on cell-surface
MHC (major histocompatibility complex) antigens. However,
the expression of MHC class II and costimulatory proteins
by iDCs is low and hence these cells have little or no capac-
ity to present antigens until they differentiate into mDCs.
The mDCs lose their capacity to phagocytose particles and
process antigens, but are induced by proinflammatory stim-
ulants to express high levels of MHC class II alloantigens on
their surface, along with processed antigenic peptides and
costimulatory surface markers such as CD40, CD80, and
CD86 (see Fig. 1). Thus, by expressing costimulatory mole-
cules, mDCs can induce a second signal in T cells that,
together with the first signal generated by TCR in response
to the MHC-peptide complex, results in an immune rather
than a tolerogenic/anergic response.
The changes in receptor expression from DC precursors
to iDCs and to mDCs enables DCs as they mature to
respond to a new set of ligands with consequent changes
in the trafficking pattern of DCs [3]. For example, as pre-
cursors of DC become iDCs they become responsive to a
wide range of proinflammatory stimuli and migrate towards
sites of infections and injuries [2–5]. The iDCs express
many receptors for proinflammatory cytokines as well as
chemoattractant factors which equip iDCs with the capac-
ity to respond to many exogenous and endogenous
danger signals [4]. Chemoattractant receptors enable
iDCs to migrate towards inflammatory sites where
chemoattractants are being produced. Once they are
there, they phagocytize and process self-antigens from
cellular debris and foreign antigens from invading microor-
ganisms. The interaction of chemoattractants with their
receptors initiates a signal-transduction cascade that, in
addition to activating cell migration, activates a number of
genes, resulting in the production and secretion of a
variety of mediators and effector molecules including
cytokines such as IL-1, IL-2, IL-4, IL-12, IL-15, and TGF-β
(transforming growth factor-β) chemokines ([6,7] and
unpublished observations).
Expression of chemokine receptors by
dendritic cells
The presence of ‘danger’ signals such as inflammatory
mediators and components of infectious organisms at the
peripheral inflammatory site serve to induce the maturation
of iDCs [4]. As DCs mature, they lose many of their recep-
tors, but they gain CCR7 and CXCR5, which enable them
to migrate along concentration gradients of constitutively
produced chemokines such as SLC/CCL21, ELC/CCL19,
and BLC/CXCL13 to the site of origin of these
chemokines in lymphoid tissues [5] (Fig. 2). It is in the
well-organized lymphoid tissues that mDCs expressing a
particular peptide–MHC complex have a better chance of
encountering those few T lymphocytes expressing a TCR
that can recognize the antigen on the DC, thus initiating
an immune response. By directing the trafficking and
homing of iDCs and mDCs, respectively, chemokine
receptors therefore presumably play a crucial role in the
uptake and delivery of antigenic signals and initiation of
adaptive immune responses.
Role of defensins in adaptive immunity
A number of disparate nonchemokine ligands have been
shown to have the ability to activate chemokine receptors
Figure 1
In vitro stages of differentiation and maturation of dendritic cells. The phenotypic and functional characteristics of immature and mature dendritic
cells are compared. APC, antigen-presenting cell; DC, dendritic cell; GM-CSF, granulocyte/macrophage-colony-stimulating factor; HLA-DR,
histocompatibility leukocyte antigen; LPS, lipopolysaccharide; MLR, mixed leukocyte reaction; TNF, tumor necrosis factor.
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on iDCs and as a consequence to have major effects on
adaptive immune responses. One example is the
defensins, which interact with chemokine receptors. We
have shown that β defensins interact with cells express-
ing CCR6, the receptor for a chemokine known as
LARC/MIP-3α/CCL20, present on iDCs, resting
memory CD4 cells, and a subset of B lymphocytes [8].
Defensins at micromolar concentrations have direct
microbicidal activities, but at 1/10 to 1/100 micromolar
concentrations, the β defensins derived from ker-
atinocytes and mucosal epithelial cella activate and
induce chemotactic migration of CCR6+ cells. Although
the receptor for α defensins has not been identified, it is
inhibitable by pertussis toxin and therefore also is a Gαi-
protein-coupled receptor, like the chemokine receptors
[9]. The possibility that α defensins interact with
chemokine-like receptors on iDCs may account for our
previous findings showing that α defensins are remark-
ably potent adjuvants that enhance both T-helper (Th)1
cell-mediated responses and Th2-type humoral antibody
responses in mice to concomitantly administered anti-
gens such as keyhole limpet hemocyanin (KLH) and
ovalbumin [10,11].
Role of receptors on dendritic cells in
breaking tolerance to ‘self-tumor’ antigens
The observed adjuvant effects of defensins on soluble
antigens led us to examine the ability of β defensins to
augment a weaker anti-tumor response. The anti-tumor
effect of β defensins and selected chemokines was tested
by linking them to an idotypic immunoglobulin antigen (Id)
or its unique Fv Fragment (sFv) present on malignant
murine lymphomas [12]. These linked fusion constructs
were administered either as a naked DNA vaccine intra-
muscularly or as recombinant fusion proteins. The results
revealed that Id or sFv by themselves were not immuno-
genic [12,13]. Furthermore, mixtures of chemokines or
murine β defensins (mBD2 and mBD3) and Id had no sig-
nificant protective effect. Only when the β defensins or
chemokines were covalently linked to the tumor antigen
was an immunogenic anti-tumor effect achieved [12,13].
The Id–mBD2 fusion product yielded more cellular than
humoral immunity, while Id–mBD3 induced predominantly
antibody responses to the tumor antigens. Consequently,
mBD2, but not mBD3, had a protective effect and induced
prolonged tumor survival in 20–50% of mice challenged
with tumors. The humoral immune effects of mBD3 fusion
products resembled that of MDC/CCL22, which interacts
with CCR4 and is known to favor the induction of TH2
responses. Alternatively, mBD2 mimicked the cell-medi-
ated anti-tumor effects of MIP3α/CCL20, which also inter-
acts with CCR6 and MCP3/CCL7, a chemokine that is
known to interact with chemokine receptors CCR1,
CCR2, and CCR3, which favors Th1-cell-mediated
immune responses [14]. These findings suggest that the
identity of the chemokine or defensin–receptor interaction
on iDCs plays a role in determining whether humoral or
cellular immunity is induced [13]. Because only Id anti-
gens fused to chemokines or defensins were effective in
inducing an immune response, and because these fused
proteins were still functionally active inducers of in vitro
chemotaxis of iDCs [13], presumably interaction of the
fusion product with the chemokine receptor favors antigen
uptake and processing and subsequent presentation by
antigen-presenting cells. This hypothesis is supported by
the inability of control fusion constructs (using mutated or
an inactive β pro-defensin moiety) that do not bind or acti-
vate the receptors on iDCs to elicit any immune response
[13]. Thus, linking of sFv antigen to a functional
chemokine or defensin, like a postage stamp, may help
deliver the antigen more effectively to the iDCs in part by
directing the migration of iDCs to the site of antigen pro-
duction when used as a DNA vaccine. Since Id antigen
actually represents an overexpressed normal clonal B-cell
immunoglobulin product, these experiments actually break
tolerance and produce an immune response to a self-
antigen: in other words, they induce an ‘autoimmune’
response to the tumor.
Role of receptors on dendritic cells in
autoimmune myositis
There have been several recent reports of a second type
of nonchemokine ligand, namely tyrosyl tRNA synthetase
(TyrRS) being chemotactic for neutrophils by selectively
interacting with one of the receptors for IL-8, CXCR-1
[15,16]. This surprising result motivated us to evaluate the
chemoattractant activities of other aminoacyl tRNA syn-
thetases (aaRSs) to which some patients with idiopathic
inflammatory myopathic (dermatomyositis and polymyositis
or related diseases) develop autoantibodies [17].
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Figure 2
Changes in chemokine receptor expression in the course of maturation
of dendritic cells. The in vivo traffic route of dendritic cells as they
mature is depicted, along with the changes in the expression of
chemokine receptors. BM, bone marrow; CC indicates the presence of
adjoining cysteines in sequence; DC, dendritic cell; iDC, immature
dendritic cell; mDC, mature dendritic cell.S186
Of the five aaRSs tested, two to which patients had
autoantibodies were shown to be chemotactic for T lym-
phocytes, IL-2-activated monocytes, and immature den-
dritic cells (iDCs). They were not chemotactic for
neutrophils, unstimulated monocytes, or mature dendritic
cells (mDCs) (Table 1).
We tested histidyl tRNA synthetase (HisRS), the most fre-
quently targeted aaRS in myositis, since 20–30% of
patients have autoantibodies to it. We also tested the N-
terminal coiled-coil domain of HisRS 1–48 with which
autoantibodies react and found it to be a less potent
chemotactic stimulant of IL-2-activated monocytes and T
cells but not of iDCs. In contrast, a construct lacking the
N-terminal domain (HisRS 61–509) was not chemotactic
for any leukocyte subset. Furthermore, a mutated variant of
HisRS, MHRS, also lacked any chemotactic activity.
Next, we investigated the possibility that HisRS utilized a
G-coupled protein receptor by testing its susceptibility to
pertussis toxin. Indeed, the chemotactic response of
HisRS was inhibited by this toxin. Furthermore, we exam-
ined the desensitizing effects of a panel of chemokines to
determine whether HisRS acted on a chemokine receptor.
Preincubation with either RANTES/CCL5 or MIP-1β/
CCL4, which uses CCR5, inhibited the subsequent
chemotactic response of T cells to HisRS. Conversely,
preincubation with HisRS selectively blocked the chemo-
tactic response to these chemokines. Furthermore, HisRS
was an equipotent chemoattractant for HEK293 cells
transfected with CCR5, but not for cells transfected with
CCR1 or CCR3. These observations thus identified
CCR5 as a receptor for HisRS.
Although the incidence of autoantibody formation to
asparaginyl tRNA synthetase (AsnRS) is less than 5%,
this synthetase was also chemotactic for T cells and iDCs.
We therefore tested AsnRS on a panel of cell lines trans-
fected with chemokine receptors to identify its receptors
and established that AsnRS was chemotactic for HEK293
cells transfected with CCR3. In contrast, three additional
aaRSs to which no autoantibodies have been detected,
namely seryl tRNA synthetase (SerRS), lysyl tRNA syn-
thetase (LysRS), and aspartyl tRNA synthetase (AspRS)
were not chemotactic for iDCs. Even though SerRS was
chemotactic for lymphocytes expressing CCR3, it had no
effect on iDCs. Consequently, the presence of autoanti-
bodies to an aaRS appear to correlate with the capacity of
the synthetase to have chemotactic effects on iDCs
expressing receptors, suggesting that these antigens may
contribute to myositis not only by inducing autoantibodies,
but also by attracting inflammatory cells into affected
muscle tissue. Indeed, three lines of evidence support this
hypothesis. One is that infiltrates of mononuclear cells,
including DCs, have been detected in striated muscle of
patients with myositis [18]. Another is that CCR5 as well
as CCR2 have been detected on cells infiltrating inflamed
muscle tissue, and the degenerating and regenerating
muscles themselves express low levels of CCR5 in myosi-
tis [19–21]. And finally, injection of naked DNA coding for
HisRS into mice induces local myositis at the injection site
[22].
Role of receptors on dendritic cells in
pathogenesis of autoimmune disease
Another group of nonchemokine ligands that are well
known to interact with CCR5 and CXCR4 are the enve-
lope proteins gp120 and gp41 of HIV-1 (as reviewed
[23]). They initially interact with CD4, and the result is a
conformational change that enables the envelope proteins
to interact with chemokine receptors as a prerequisite for
the entry of HIV-1 into cells. This interaction with
chemokine receptors is evident from the inability of mono-
cytotropic HIV-1 to infect subjects homozygous for the
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Table 1
Chemotactic activity of aminoacyl tRNA synthetases
Leukocyte subpopulation HisRS MHRS 1–48 HisRS AsnRS SerRS AspRS LysRS
Neutrophils – – – – – – –
Monocytes – – – – – – –
IL-2-activated monocytes + – + N.D. N.D. N.D. N.D.
Lymphocytes + – + + + ± ±
CD8 T cells ± – ± N.D. N.D. N.D. N.D.
CD4 T cells + – + + N.D. N.D. N.D.
iDCs + – + + – + –
mDCs – – – – N.D. N.D. N.D.
–, absent response; +, positive response; ±, variable response; N.D., not done. AsnRS, asparaginyl tRNA synthetase; AspRS, aspartyl tRNA
synthetase; HisRS, histidyl tRNA synthetase; iDC, immature dendritic cells; LysRS, lysyl tRNA synthetase; mDCs, mature dendritic cells; MHRS,
mutated HisRS; SerRS, seryl tRNA synthetase.S187
∆32 CCR5 variant [24,25]. This variant is retained in the
cytoplasm and is not expressed on the cell surface. Fur-
thermore, heterozygotes develop AIDS more slowly than
homozygotes [26]. It is relevant to our findings that sub-
jects heterozygous for ∆32 CCR5 also have a lower inci-
dence of autoimmune diseases, including rheumatoid
arthritis, Crohn’s disease, and multiple sclerosis [27–30].
The mechanistic basis for the lower incidence of autoim-
munity in such heterozygotes is elucidated to some extent
by the phenotypic characteristics of CCR5 knockout mice
[31]. Such mice have reduced resistance to several micro-
bial pathogens and are protected from lipopolysaccharide-
induced endotoxemia. The finding that cellular immune
responses of CCR5-deficient mice are diminished sug-
gests that ligation of CCR5 promotes Th1 polarization of
immune responses [32]. This hypothesis is supported by
observations that ligands, such as MIP-1α and RANTES,
that utilize CCR5 favor induction of cytokine production by
Th1 cells [32]. These reports suggest that CCR5 ligation
may favor the development of Th1-type autoimmune condi-
tions. Consequently, myositis may be a Th1 condition and
this may account for the low incidence of autoantibody for-
mation in these patients.
Our studies have shown that diverse chemoattractants for
iDCs also have the capacity to break self-tolerance, result-
ing in the capacity to reject tumors or promulgate autoim-
munity [33]. These findings suggest the hypothesis that
antigens with chemotactic effects for receptors expressed
by iDCs may be more effectively processed and pre-
sented to T cells, thus initiating and promulgating autoim-
mune responses or tumor immunity. Our observations
suggest that the proinflammatory chemokine-like proper-
ties of some proteins provide a danger signal that not only
amplifies innate inflammatory reactions, but also elicits
adaptive immune responses, including the formation of
autoantibodies.
Furthermore, the observation that the administration of an
idiotypic tumor antigen derived from lymphomas, when
linked to chemokines or β defensins as a fusion product,
can apparently also break the tolerant or anergic state to
that antigen further highlights the immuno-enhancing/adju-
vant consequences of antigens interacting with receptors
on iDCs. This idea is certainly supported by abundantly
documented observations that antigens interacting with
receptors on antigen-presenting cells are 10,000-fold
more effectively processed by the MHC class II pathway
than are pinocytosed antigens [34].
Therapeutic implications
Of course, many questions remain unanswered. For
example, it is unclear why only a minority of patients with
myositis develop autoantibodies selectively to aaRS.
Perhaps myositis is predominantly based on Th1 cytokine
responses, with a lower incidence of autoantibody pro-
duction than is seen in Th2 autoimmune-based conditions.
Since aaRSs are present in all nucleated cell types, the
selective targeting of these particular autoantigens to
muscle tissues in myositis is another puzzle awaiting solu-
tion. Nevertheless, our observations suggest that the
autoantigenic aaRS has a causal role in this disease
process and identifies several chemokine receptors,
namely CCR5 and CCR3, as potential targets for thera-
peutic intervention in patients with autoimmune myositis.
Concluding remarks
Overall, our results lead to the prediction that ligands that
interact with receptors on DC are likely to have immuno-
adjuvant effects. This suggests that the relatively small
proportion of self-antigens that are thought to be capable
of inducing autoimmune conditions are more likely than
most self-antigens to have domains that mimic ligands for
receptors on iDCs. The observation that some aaRSs fall
into that category is provocative, but additional autoanti-
gens need to be examined to support this hypothesis.
Glossary of terms
aaRS = aminoacyl tRNA synthetase; AsnRS = asparaginyl
tRNA synthetase; AspRS = aspartyl tRNA synthetase; CC
indicates the presence of adjoining cysteines in sequence;
CCL = CC chemokine ligand; CCR = CC chemokine
receptor; DC = dendritic cell; HisRS = histidyl tRNA syn-
thetase; Id = idiotypic immunoglobulin; iDC = immature
dendritic cell; LARC = liver- and activation-regulated
chemokine; LysRS = lysyl tRNA synthetase; mBD = murine
β defensin; MCP = monocyte chemotactic protein; MDC =
macrophage-derived chemokine; mDC = mature dendritic
cell; MHRS = mutated HisRS; MIP = macrophage inflam-
matory protein; RANTES = regulated-upon-activation
normal T cell expressed and secreted; SerRS = seryl tRNA
synthetase; sFv = lymphoma-specific single-chain immuno-
globulin (consisting of linked Vh and V2 domains of
lymphoma immunoglobulin).
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